As the incretin action of GIP seems to be impaired in patients with type 2 diabetes1, it might be postulated that a stimulation of GLP‐1 and an inhibition of GIP secretion could be a therapeutic objective in overweight patients with type 2 diabetes. Here, GIP is linked to type 2 diabetes mellitus.